Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06583057
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-23
Brief Title:
Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma a Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the clinical outcomes of Thermal ablation with those of thyroid lobectomy in patients with subcapsular papillary thyroid microcarcinoma
Detailed Description:
The global incidence of papillary thyroid microcarcinoma PTMC has increased rapidly in recent decades because of improved ultrasound US detection and fine needle aspiration biopsy and has primarily contributed to the surge in cases of thyroid carcinoma Given the indolent characteristics of most PTMCs the American Thyroid Association guidelines recommend active surveillance for low-risk PTMC to prevent over-treatment Nevertheless in many countries active surveillance poses challenges including patient anxiety limited medical resources and insurance coverage limitations when adopted Furthermore many patients prefer treatment rather than active surveillance due to anxiety a meta-analysis showed that a significant proportion of patients 87-32 who underwent delayed surgery without tumor progression during active surveillance Thyroid lobectomy TL replacing total thyroidectomy is recommended as the first-line treatment for PTMC by several guidelines However there were still concerns remain regarding lifelong hormone replacement therapy surgery-related complications and the potential over-treatment associated with TL
Thermal ablation TA has emerged as a viable alternative for the managing of PTMC within the thyroid gland as evidenced by studies conducted across various Asian and European countries It has been endorsed as an alternative treatment strategy to TL in clinical guidelines issued by multiple professional associations in Europe Asia and North America However controversy persists regarding its usefulness for subcapsular PTMC because of concerns about potential extrathyroidal extension ETE or occult lymph node metastasis LNM which may impact disease progression post-treatment There are also technical challenges and safety issues when ablating subcapsular lesions To date a limited number of studies have reported the short-term efficacy of TA in treating subcapsular PTMCHowever these studies were constrained by small sample sizes and the absence of comparative analyses between the first-line treatment option TL and TA Consequently further research is needed to fully understand the role of TA in the therapeutic management of subcapsular PTMC and its potential as an alternative to TL
Therefore the aim of this multicenter study was to compare the clinical outcomes of TA with those of TL in patients with subcapsular PTMC
Thermal ablation TA has emerged as a viable alternative for the managing of PTMC within the thyroid gland as evidenced by studies conducted across various Asian and European countries It has been endorsed as an alternative treatment strategy to TL in clinical guidelines issued by multiple professional associations in Europe Asia and North America However controversy persists regarding its usefulness for subcapsular PTMC because of concerns about potential extrathyroidal extension ETE or occult lymph node metastasis LNM which may impact disease progression post-treatment There are also technical challenges and safety issues when ablating subcapsular lesions To date a limited number of studies have reported the short-term efficacy of TA in treating subcapsular PTMCHowever these studies were constrained by small sample sizes and the absence of comparative analyses between the first-line treatment option TL and TA Consequently further research is needed to fully understand the role of TA in the therapeutic management of subcapsular PTMC and its potential as an alternative to TL
Therefore the aim of this multicenter study was to compare the clinical outcomes of TA with those of TL in patients with subcapsular PTMC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None